California-based real-world information platform Atropos Well being has secured $33 million in Sequence B funding.
Valtruis led the funding spherical, which included new buyers McKesson Ventures, Merck GHI Fund and Cencora Ventures.
Current buyers Emerson Collective, Breyer Capital and Presidio Ventures additionally participated within the spherical.
Mike Spadafore, managing director of Valtruis, will be a part of the corporate’s board of administrators.
WHAT IT DOES
The California-based firm, based in 2019, provides AI improvements, proof technology, analytics augmentation and information analysis to assist physicians entry real-world proof to information medical choices and analysis.
The corporate additionally provides a platform dubbed ChatRWD, an LLM-powered chat device for medical analysis that goals to remove hallucination threat by using the corporate’s real-world information platform, GENEVA OS.
Atropos will use the funds to increase into oncology and specialty care with the assistance of one among its new buyers Cencora, previously AmerisourceBergen. Cencora is a drug-wholesale firm and contract-research group.
The funds may also help the complete launch of ChatRWD.
“The way forward for value-based care is about making evidence-based choices; persevering with to ship high-quality proof to well being programs permits them to implement packages and processes that drive distinctive affected person outcomes whereas minding the underside line,” Dr. Brigham Hyde, CEO and cofounder of Atropos Well being, instructed MobiHealthNews in an electronic mail.
“Proof is extra vital than ever, particularly in relation to oncology care. It is evolving continually, and the stakes are extremely excessive. By investing in our options and sustaining transparency in our methodologies, we empower well being system and life science companions to make choices based mostly on real-world proof for most cancers sufferers and all sufferers, fostering really personalised medication and remodeling the panorama of healthcare.”
MARKET SNAPSHOT
Final 12 months, Atropos introduced it accomplished a strategic financing spherical, a 12 months after securing $14 million in a Sequence A funding spherical.
The corporate additionally introduced a partnership with data-sharing expertise platform Datavant, that might enable every firm’s members to entry the opposite firm’s choices.
Earlier this 12 months, Atropos introduced that healthcare-data analytics firm Arcadia had joined its well being portfolio. This may enable Arcadia’s supplier prospects and life sciences customers to entry its datasets for value-based care and medical decision-making.
The corporate has additionally partnered with medical analytics and affected person chart summarization firm KAID Well being, healthcare-data firm SEQSTER and Janssen Analysis & Growth, a Johnson & Johnson firm.